Subject: Resverlogix Presents New Complement Data and Establishes RenalClinical Advisory Board at the 53rd Annual Euro
--->pean Renal Association -European Dialysis & Transplant Association Congress (ERA-EDTA)
PLAIN TEXT:
News Release Issued: May 24, 2016 (4:54pm MDT)
Resverlogix Presents New Complement Data and Establishes Renal Clinical
Advisory Board at the 53rd Annual European Renal Association - European
Dialysis & Transplant Association Congress (ERA-EDTA)
"Apabetalone, a selective bromodomain extra-terminal (BET) protein inhibitor
that significantly decreases abundance and activity of complement proteins"
CALGARY, May 24, 2016 /CNW/ -A Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) announces that new data was presented at the ERA-EDTA
Congress in Vienna, Austria in a poster titled: "Apabetalone (RVX-208), a
Selective Bromodomain and Extra-Terminal (BET) Protein Inhibitor, Decreases
Abundance and Activity of Complement Proteins in Vitro, in Mice and in
Clinical Studies". The Company is also pleased to announce the formation of an
International Renal Clinical Advisory Board (RCAB) for the future development
of apabetalone into expanded renal indications.
New Complement Data Announced at ERA-EDTA Congress a{ €}" Vienna, Austria
The immune system is the body's way of protecting itself from attacking
foreign invaders, such as bacteria, viruses, illness, and disease. The
complement cascade is part of this protective response, however pathological
activation of the cascade underlies multiple human diseases including several
inflammatory, autoimmune, neurodegenerative and infectious diseases.
New data demonstrated that when exposed to apabetalone, primary human liver
cells significantly downregulate the expression of complement components. This
was observed at both the gene expression and protein level, and occurred at
steady state (when unstimulated) and when the cells were stimulated with
factors known to cause inflammation and immune response activation. This is
particularly important in conditions where these factors are overactive or
present in excessive quantities. Moreover, in an apabetalone treated mouse
model, where mouse liver cells are replaced with human liver cells, reductions
in expression of components C4, C9 and MBL2 mRNA of the complement cascade,
decreased by 36 percent, 46 percent and 61 percent respectively.A To
establish if the observed decrease in protein abundance affected activity,
hemolytic assays were performed on 11 plasma samples from patients with
cardiovascular disease (CVD) at baseline, and after 26 weeks of apabetalone
treatment. Results showed a significant decrease in activity of approximately
26 percent (p<0.01) in both assays. No increase in infections was reported in
phase 2 trials.
This effect of apabetalone treatment on complement component expression and
cascade activity may have an impact on the pathologic activation of this
cascade in Chronic Kidney Disease (CKD). The potential of apabetalone for the
treatment of high-risk diabetes and CKD patients is currently being explored
in the Company's Phase 3 BETonMACE clinical study.
Dr. Kamyar Kalantar-Zadeh, Chairman of the RCAB, stated, "BET inhibition with
apabetalone represents a novel and compelling approach for diabetes and CKD
treatment. This data in combination with previously published findings on
novel biomarkers and pathways affected by select BET inhibition with known
roles in CVD and CKD such as, coagulation, vascular calcification and
inflammation, provide a potentially unique and multifactorial approach to
disease reduction. The RCAB intend to examine expanded opportunities in renal
disease where patients have a significant risk for major adverse cardiac
events (MACE) such as death, stroke, heart failure and myocardial infarction".
"This new data is an important step for the Company as we continue to develop
our proprietary BET data for high risk CVD patients and apply these learnings
into additional indications in kidney and renal orphan diseases," said Mr.
Donald McCaffrey, President and CEO. "The data showing that select BET
inhibition is modulating key pathways and proteins known to play a role in
renal disease, is directly responsible for attracting world-class leaders in
the field of renal disease research to help expand and direct our efforts."
Members of the Resverlogix International Renal Clinical Advisory Board:
Dr. Kamyar Kalantar-Zadeh (Chair): Dr. Kalantar-Zadeh is Professor and Chief,
Division of Nephrology and Hypertension at University of California, Irvine.
Dr. Kalantar-Zadeh is the founder and director of the Harold Simmons Center
for Kidney Disease Research and Epidemiology. Among his numerous appointments
in the renal field Dr. Kalantar-Zadeh is Associate Editor of several
peer-reviewed journals including Nephrology Dialysis Transplantation (NDT),
American Journal of Kidney Diseases (AJKD), Cardiorenal Medicine (CRM),
Seminars in Dialysis, sarcopenia and Muscle (JCSM), and a member of the
editorial board of Journal of Kidney International (KI), Journal of American
Society Nephrology (JASN), Nature Reviews Nephrology, American Journal of
Nephrology (AJN). Dr. Kalantar-Zadeh has authored 3 textbooks and over 500
peer reviewed publications.A A
Dr. Carmine Zoccali:A Dr. Zoccali is a specialist in Renal Diseases (Pisa
University) and Hypertension. Dr. Zoccali's appointments include: Director,
Division of Nephrology, Hypertension and Renal Transplantation, Ospedali
Riuniti, Reggio Cal, Italy; Chief, CNR-IBIM Clinical Epidemiology and
Pathophysiology of Renal Diseases and Hypertension; Professor, Postgraduate
Schools of Nephrology, Palermo, Catania and Messina Universities. Dr.
Zoccali's current editorial positions include: Editor in Chief, Nephrology
Dialysis and Transplantation, Academic Editor, (Nephrology) PlosOne, and
Editorial Board member, Journal of the American Society of Nephrology (JASN).
Editorial Board member, Clinical Journal of the American Society of Nephrology
(cJASN) and Editorial Board member, Kidney International (KI). Dr. Zoccali has
over 402 papers in international peer-reviewed, Pubmed indexed journals.
Dr. Marcello Tonelli: Dr. Tonelli is Associate Vice-President (Research) at
the University of Calgary. Dr. Tonelli was the recipient of the 2013 United
States National Kidney Foundation Medal for Distinguished Service and the
Kidney Foundation of Canada's 2013 Medal for Research Excellence for changing
nephrology practice in Canada and beyond. Along with the two other team
co-leads, he received a Top Canadian Achievements in Health Research Award
from the CIHR-CMAJ in 2013 for his work with the Interdisciplinary Chronic
Disease Collaboration. He was elected a fellow of the Canadian Academy of
Health Sciences in 2012 and a member of the American Society for Clinical
Investigation in 2014. He was named a "Highly Cited" researcher in 2015 by
Thomson-Reuters, corresponding to a rank in the top 1% by citations of all
researchers worldwide for field and publication year.
Dr. Vincent Brandenburg: Dr. Brandenburg is Nephrologist, Associate Professor
and Senior Consultant at the Department of Cardiology, Intensive Care Medicine
and Vascular Medicine, University Hospital of the RWTH Aachen, Germany. Dr.
Brandenburg has been leader of the German Calciphylaxis registry
(www.calciphylaxie.de) since 2007. He is a board member of the ERA-EDTA
scientific working group Chronic Kidney Disease a{ €}" Mineral and Bone Disorder
(CKD-MBD). Dr. Brandenburg has authored or co-authored over 140 articles in
peer-reviewed journals. These articles have had the primary focus upon chronic
kidney disease a{ €}" mineral and bone disorder, cardiorenal syndrome, and
calciphylaxis. He is a member of the German and European Societies of
Nephrology and the Societies of Cardiology.
Dr. Srinivasan Beddhu: Dr. Beddhu, MD is a tenured Professor of Medicine at
the University of Utah School of Medicine. He is Board Certified in Internal
Medicine and Nephrology. Dr. Beddhu received his medical degree from Stanley
Medical College, Chennai, India. His clinical and research interests include
hypertension, chronic kidney disease progression and complications and
end-stage renal disease. Dr. Beddhu's research is funded primarily by NIH
grants. He has served in several national committees including NIH panels,
American Society of Nephrology Research Committee and NKF clinical practice
guidelines committee. Dr. Beddhu has published about 100 articles including
peer-reviewed publications, editorials and book chapters.A
Dr. Mathias Haarhaus: Dr. Haarhaus is a Consultant Nephrologist at the
Department of Nephrology, Karolinska University Hospital, Stockholm, Sweden,
where he is head of the Bone and Mineral Program. His research at the Division
of Renal Medicine, Karolinska Institutet, mainly focuses on the link between
skeletal disorders and cardiovascular complications in chronic kidney disease,
with a special focus on alkaline phosphatase. He is an active member of the
Chronic Kidney Disease a{ €}" Mineral and Bone Disorder (CKD-MBD) working group
of the European Renal Association a{ €}" European Dialysis and Transplantation
Association (ERA-EDTA) and a member of the Guidelines Committee of the Swedish
Society of Nephrology.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small
molecule that is a selective BET (bromodomain and extra-terminal) inhibitor.
BET bromodomain inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is the first and only BET inhibitor
selective for the second bromodomain (BD2) within the BET protein called BRD4.
This selective inhibition of apabetalone on BD2 produces a specific set of
biological effects with potentially important benefits for patients with
diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus
(DM), chronic kidney disease (CKD), Alzheimer's disease, Orphan diseases, and
peripheral artery disease, while maintaining a well described safety profile.
Apabetalone is the only selective BET bromodomain inhibitor in human clinical
trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients with
type 2 DM and low high-density lipoprotein (HDL).
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
For further information please visitA www.resverlogix.com.
Follow us via: Twitter
@Resverlogix_RVXA (https://twitter.com/resverlogix_rvx), or on our blog
atA http://www.resverlogix.com/blogA
This news release may contain certain forward-looking information as defined
under applicable Canadian securities legislation, that are not based on
historical fact, including without limitation statements containing the words
"believes", "anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions. In
particular, this news release includes forward looking information relating to
the potential role of apabetalone in the treatment of CVD, DM, CKD, complement
component expression, Alzheimer's disease, Orphan diseases, and peripheral
artery disease. Our actual results, events or developments could be materially
different from those expressed or implied by these forward-looking statements.
We can give no assurance that any of the events or expectations will occur or
be realized. By their nature, forward-looking statements are subject to
numerous assumptions and risk factors including those discussed in our Annual
Information Form and most recent MD&A which are incorporated herein by
reference and are available through SEDAR atA www.sedar.com. The
forward-looking statements contained in this news release are expressly
qualified by this cautionary statement and are made as of the date hereof. The
Company disclaims any intention and has no obligation or responsibility,
except as required by law, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
SOURCE Resverlogix Corp.
A
This email is being delivered to you by:
Resverlogix Corp.
300, 4820 Richard Road SW
Calgary, ABA T3E 6L1
E: info@resverlogix.com
Ph: 403-254-9252
You may unsubscribe at any time using the link below.
A
To unsubscribe or change your settings click here:
http://resverlogix.mediaroom.com/index.php?s=subscribe&code=y78VyFxfyMTZBVoD4Re-dJELzOr68xke
HTML CONTENT:
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN" "http://www.w3.org/TR/REC-html40/loose.dtd">
<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"></head><body>
<a href="http://www.resverlogix.com"><img src="http://resverlogix.mediaroom.com/file.php/197092/RVX_logo_RGB.jpg" bord
--->er="0" align="right" height="100" width="198" style="float: right; margin: 0px 0px 10px 10px;"></a>
<p style="font-family: arial, verdana; color: #333333;">News Release Issued: May 24, 2016 (4:54pm MDT)</p>
<h1 style="font-family: arial, verdana; font-size: 1.2em;">Resverlogix Presents New Complement Data and Establishes Re
--->nal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Associa
--->tion Congress (ERA-EDTA)</h1>
<p style="font-family: arial, verdana; TEXT-ALIGN: CENTER;"><i>"Apabetalone, a selective bromodomain extra-terminal (B
--->ET) protein inhibitor that significantly decreases abundance and activity of complement proteins"</i></p>
<p style="font-family: arial, verdana;"><span>CALGARY</span>, <span>May 24, 2016</span> /CNW/ - Resverlogix Corp. ("Re
--->sverlogix" or the "Company") (TSX:RVX) announces that new data was presented at the ERA-EDTA Congress in <span>Vienna,
---> Austria</span> in a poster titled: "Apabetalone (RVX-208), a Selective Bromodomain and Extra-Terminal (BET) Protein I
--->nhibitor, Decreases Abundance and Activity of Complement Proteins in Vitro, in Mice and in Clinical Studies". The Comp
--->any is also pleased to announce the formation of an International Renal Clinical Advisory Board (RCAB) for the future
--->development of apabetalone into expanded renal indications. </p>
<p style="font-family: arial, verdana;"><b>New Complement Data Announced at ERA-EDTA Congress - <span>Vienna, Austria<
--->/span></b></p>
<p style="font-family: arial, verdana;">The immune system is the body's way of protecting itself from attacking foreig
--->n invaders, such as bacteria, viruses, illness, and disease. The complement cascade is part of this protective respons
--->e, however pathological activation of the cascade underlies multiple human diseases including several inflammatory, au
--->toimmune, neurodegenerative and infectious diseases.</p>
<p style="font-family: arial, verdana;">New data demonstrated that when exposed to apabetalone, primary human liver ce
--->lls significantly downregulate the expression of complement components. This was observed at both the gene expression
--->and protein level, and occurred at steady state (when unstimulated) and when the cells were stimulated with factors kn
--->own to cause inflammation and immune response activation. This is particularly important in conditions where these fac
--->tors are overactive or present in excessive quantities. Moreover, in an apabetalone treated mouse model, where mouse l
--->iver cells are replaced with human liver cells, reductions in expression of components C4, C9 and MBL2 mRNA of the com
--->plement cascade, decreased by 36 percent, 46 percent and 61 percent respectively. To establish if the observed decrea
--->se in protein abundance affected activity, hemolytic assays were performed on 11 plasma samples from patients with car
--->diovascular disease (CVD) at baseline, and after 26 weeks of apabetalone treatment. Results showed a significant decre
--->ase in activity of approximately 26 percent (p<0.01) in both assays. No increase in infections was reported in phas
--->e 2 trials. </p>
<p style="font-family: arial, verdana;">This effect of apabetalone treatment on complement component expression and ca
--->scade activity may have an impact on the pathologic activation of this cascade in Chronic Kidney Disease (CKD). The po
--->tential of apabetalone for the treatment of high-risk diabetes and CKD patients is currently being explored in the Com
--->pany's Phase 3 BETonMACE clinical study.</p>
<p style="font-family: arial, verdana;">Dr. <span>Kamyar Kalantar-Zadeh</span>, Chairman of the RCAB, stated, "BET inh
--->ibition with apabetalone represents a novel and compelling approach for diabetes and CKD treatment. This data in combi
--->nation with previously published findings on novel biomarkers and pathways affected by select BET inhibition with know
--->n roles in CVD and CKD such as, coagulation, vascular calcification and inflammation, provide a potentially unique and
---> multifactorial approach to disease reduction. The RCAB intend to examine expanded opportunities in renal disease wher
--->e patients have a significant risk for major adverse cardiac events (MACE) such as death, stroke, heart failure and my
--->ocardial infarction".</p>
<p style="font-family: arial, verdana;">"This new data is an important step for the Company as we continue to develop
--->our proprietary BET data for high risk CVD patients and apply these learnings into additional indications in kidney an
--->d renal orphan diseases," said Mr. <span>Donald McCaffrey</span>, President and CEO. "The data showing that select BET
---> inhibition is modulating key pathways and proteins known to play a role in renal disease, is directly responsible for
---> attracting world-class leaders in the field of renal disease research to help expand and direct our efforts."</p>
<p style="font-family: arial, verdana;"><b>Members of the Resverlogix International Renal Clinical Advisory Board:</b>
---></p>
<p style="font-family: arial, verdana;"><b>Dr. <span>Kamyar Kalantar-Zadeh</span> (Chair):</b> Dr. Kalantar-Zadeh is P
--->rofessor and Chief, Division of Nephrology and Hypertension at <span>University of California, Irvine</span>. Dr. Kala
--->ntar-Zadeh is the founder and director of the Harold Simmons Center for Kidney Disease Research and Epidemiology. Amon
--->g his numerous appointments in the renal field Dr. Kalantar-Zadeh is Associate Editor of several peer-reviewed journal
--->s including Nephrology Dialysis Transplantation (NDT), American Journal of Kidney Diseases (AJKD), Cardiorenal Medicin
--->e (CRM), Seminars in Dialysis, sarcopenia and Muscle (JCSM), and a member of the editorial board of Journal of Kidney
--->International (KI), Journal of American Society Nephrology (JASN), Nature Reviews Nephrology, American Journal of Neph
--->rology (AJN). Dr. Kalantar-Zadeh has authored 3 textbooks and over 500 peer reviewed publications. </p>
<p style="font-family: arial, verdana;"><b>Dr. <span>Carmine Zoccali</span>:</b> Dr. Zoccali is a specialist in Renal
---> Diseases (<span>Pisa</span> University) and Hypertension. Dr. Zoccali's appointments include: Director, Division of N
--->ephrology, Hypertension and Renal Transplantation, Ospedali Riuniti, Reggio Cal, <span>Italy</span>; Chief, CNR-IBIM C
--->linical Epidemiology and Pathophysiology of Renal Diseases and Hypertension; Professor, Postgraduate Schools of Nephro
--->logy, <span>Palermo</span>, Catania and Messina Universities. Dr. Zoccali's current editorial positions include: Edito
--->r in Chief, Nephrology Dialysis and Transplantation, Academic Editor, (Nephrology) PlosOne, and Editorial Board member
--->, Journal of the American Society of Nephrology (JASN). Editorial Board member, Clinical Journal of the American Socie
--->ty of Nephrology (cJASN) and Editorial Board member, Kidney International (KI). Dr. Zoccali has over 402 papers in int
--->ernational peer-reviewed, Pubmed indexed journals.</p>
<p style="font-family: arial, verdana;"><b>Dr. <span>Marcello Tonelli</span>:</b> Dr. Tonelli is Associate Vice-Presid
--->ent (Research) at the <span>University of Calgary</span>. Dr. Tonelli was the recipient of the 2013 United States Nati
--->onal Kidney Foundation Medal for Distinguished Service and the Kidney Foundation of <span>Canada's</span> 2013 Medal f
--->or Research Excellence for changing nephrology practice in <span>Canada</span> and beyond. Along with the two other te
--->am co-leads, he received a Top Canadian Achievements in Health Research Award from the CIHR-CMAJ in 2013 for his work
--->with the Interdisciplinary Chronic Disease Collaboration. He was elected a fellow of the Canadian Academy of Health Sc
--->iences in 2012 and a member of the American Society for Clinical Investigation in 2014. He was named a "Highly Cited"
--->researcher in 2015 by Thomson-Reuters, corresponding to a rank in the top 1% by citations of all researchers worldwide
---> for field and publication year.</p>
<p style="font-family: arial, verdana;"><b>Dr. <span>Vincent Brandenburg</span>:</b> Dr. Brandenburg is Nephrologist,
--->Associate Professor and Senior Consultant at the Department of Cardiology, Intensive Care Medicine and Vascular Medici
--->ne, University Hospital of the RWTH Aachen, <span>Germany</span>. Dr. Brandenburg has been leader of the German Calcip
--->hylaxis registry (<a href="http://www.calciphylaxie.de" rel="nofollow">www.calciphylaxie.de</a>) since 2007. He is a b
--->oard member of the ERA-EDTA scientific working group Chronic Kidney Disease - Mineral and Bone Disorder (CKD-MBD). Dr.
---> Brandenburg has authored or co-authored over 140 articles in peer-reviewed journals. These articles have had the prim
--->ary focus upon chronic kidney disease - mineral and bone disorder, cardiorenal syndrome, and calciphylaxis. He is a me
--->mber of the German and European Societies of Nephrology and the Societies of Cardiology.</p>
<p style="font-family: arial, verdana;"><b>Dr. <span>Srinivasan Beddhu</span>:</b> Dr. Beddhu, MD is a tenured Profess
--->or of Medicine at the <span>University of Utah</span> School of Medicine. He is Board Certified in Internal Medicine a
--->nd Nephrology. Dr. Beddhu received his medical degree from Stanley Medical College, <span>Chennai, India</span>. His c
--->linical and research interests include hypertension, chronic kidney disease progression and complications and end-stag
--->e renal disease. Dr. Beddhu's research is funded primarily by NIH grants. He has served in several national committees
---> including NIH panels, American Society of Nephrology Research Committee and NKF clinical practice guidelines committe
--->e. Dr. Beddhu has published about 100 articles including peer-reviewed publications, editorials and book chapters. </
--->p>
<p style="font-family: arial, verdana;"><b>Dr. <span>Mathias Haarhaus</span>:</b> Dr. Haarhaus is a Consultant Nephrol
--->ogist at the Department of Nephrology, Karolinska University Hospital, <span>Stockholm, Sweden</span>, where he is hea
--->d of the Bone and Mineral Program. His research at the Division of Renal Medicine, <span>Karolinska Institutet</span>,
---> mainly focuses on the link between skeletal disorders and cardiovascular complications in chronic kidney disease, wit
--->h a special focus on alkaline phosphatase. He is an active member of the Chronic Kidney Disease - Mineral and Bone Dis
--->order (CKD-MBD) working group of the European Renal Association - European Dialysis and Transplantation Association (E
--->RA-EDTA) and a member of the Guidelines Committee of the Swedish Society of Nephrology.</p>
<p style="font-family: arial, verdana;"><b>About Resverlogix</b></p>
<p style="font-family: arial, verdana;">Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molec
--->ule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic me
--->chanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the sec
--->ond bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a s
--->pecific set of biological effects with potentially important benefits for patients with diseases such as high-risk car
--->diovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease (CKD), Alzheimer's disease, Orphan diseases,
---> and peripheral artery disease, while maintaining a well described safety profile. Apabetalone is the only selective B
--->ET bromodomain inhibitor in human clinical trials, currently in a Phase 3 trial BETonMACE in high-risk CVD patients wi
--->th type 2 DM and low high-density lipoprotein (HDL). </p>
<p style="font-family: arial, verdana;">Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). </p>
<p style="font-family: arial, verdana;">For further information please visit <a href="http://www.resverlogix.com/" tar
--->get="_blank" rel="nofollow">www.resverlogix.com</a>. </p>
<p style="font-family: arial, verdana;">Follow us via: Twitter <a href="https://twitter.com/resverlogix_rvx" target="_
--->blank" rel="nofollow">@Resverlogix_RVX</a> (<a href="https://twitter.com/resverlogix_rvx" target="_blank" rel="nofollo
--->w">https://twitter.com/resverlogix_rvx</a>), or on our blog at <a href="http://www.resverlogix.com/blog" target="_blan
--->k" rel="nofollow">http://www.resverlogix.com/blog</a> </p>
<p style="font-family: arial, verdana;"><i>This news release may contain certain forward-looking information as define
--->d under applicable Canadian securities legislation, that are not based on historical fact, including without limitatio
--->n statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continu
--->e", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking i
--->nformation relating to the potential role of apabetalone in the treatment of CVD, DM, CKD, complement component expres
--->sion, Alzheimer's disease, Orphan diseases, and peripheral artery disease. Our actual results, events or developments
--->could be materially different from those expressed or implied by these forward-looking statements. We can give no assu
--->rance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements ar
--->e subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most r
--->ecent MD&A which are incorporated herein by reference and are available through SEDAR at </i><a href="http://www.s
--->edar.com/" target="_blank" rel="nofollow"><i>www.sedar.com</i></a><i>. The forward-looking statements contained in thi
--->s news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company di
--->sclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forw
--->ard-looking statements, whether as a result of new information, future events or otherwise.</i></p>
<p style="font-family: arial, verdana;"><b>For further information please contact:</b></p>
<p style="font-family: arial, verdana;"><b>Investor Relations<br>Email: </b><a href="mailto:ir@resverlogix.comPhone" t
--->arget="_blank" rel="nofollow"><b>ir@resverlogix.com</b></a><b><br>Phone: 403-254-9252</b></p>
<p style="font-family: arial, verdana;">SOURCE Resverlogix Corp.</p>
<p style="font-family: arial, verdana;"> </p><p style="font-family: arial, verdana;">This email is being delivered to
--->you by:</p>
<p style="font-family: arial, verdana;"><strong>Resverlogix Corp.</strong><br>
300, 4820 Richard Road SW<br>
Calgary, AB T3E 6L1<br>
E: <a href="mailto:info@resverlogix.com">info@resverlogix.com</a><br>
Ph: 403-254-9252<p style="font-family: arial, verdana;"></p></p>
<p style="font-family: arial, verdana;">You may unsubscribe at any time using the link below.</p>
<p style="font-family: arial, verdana;"> </p><p style="font-family: arial, verdana;">To unsubscribe or change your set
--->tings click here:<br><a href="http://resverlogix.mediaroom.com/index.php?s=subscribe&code=y78VyFxfyMTZBVoD4Re-dJEL
--->zOr68xke">http://resverlogix.mediaroom.com/index..php?s=subscribe&code=y78VyFxfyMTZBVoD4Re-dJELzOr68xke</a></p>
<img src="http://emailalerts.dvcotechnology.com/wf/open?upn=gP-2BY6pnKuRfCWOkuWCxKubQwNXCwR-2Bg2-2F-2B27NLNufVsh8jS-2F
--->csbpK7PQkP80Did-2FHmE8kcR6QVIjDWM-2FI6xU7F7zt5EYOMK1MJBxdXxeYEmbClbm5iKgXetAvbV-2BOsRFVPDIFULLCZ7CzDYztv2g45Cegx7gTogO
--->tNNXAxWGEKE2Ta7-2BsPtQwKcAKcU9WVzu7s419zVl-2FZO0LBHq2eD-2BaNR-2BovYxEPflyR3pplXnnz1tSYx8KZRwvQjneYaR4xfDbdPs2x3J3F1i5K
--->B9s3MCHQ-3D-3D" alt="" width="1" height="1" border="0" style="height:1px !important;width:1px !important;border-width:
--->0 !important;margin-top:0 !important;margin-bottom:0 !important;margin-right:0 !important;margin-left:0 !important;pad
--->ding-top:0 !important;padding-bottom:0 !important;padding-right:0 !important;padding-left:0 !important;"/>
</body></html>
© 2024 Canjex Publishing Ltd. All rights reserved.